Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Diabetic Nephropathy | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

Patients with type 2 diabetes (T2D) and nephropathy, also known as diabetic nephropathy (DN), are at significant risk of developing end-stage renal disease (ESRD), a condition associated with extreme morbidity/mortality and high cost of care. Current therapies are unable to prevent progressive renal decline once initial DN sets in. As a result, physicians report substantial unmet need for safe and efficacious therapies for this indication. This unmet need represents significant commercial opportunity, one that drug developers have been quick to realize. Understanding the importance of key efficacy, safety and tolerability, and nonclinical attributes to the prescribing decisions for DN will be paramount to developing a successful therapy.

Questions Answered:

  • What are the treatment drivers and goals for DN?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for DN?
  • What are the prevailing areas of unmet need and opportunity in DN?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists and nephrologists for a hypothetical new DN drug?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 30 European endocrinologists and nephrologists, fielded in January 2017.

Key companies: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, AbbVie, Bayer HealthCare, Janssen

Key drugs: Jardiance, Victoza, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), atrasentan, finerenone, canagliflozin

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
north_east
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
north_east
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
north_east
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…
north_east
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east